Bioxytran Secures $1.6 million SPA to Extinguish Note & Fund Clinical Development

Stock Information for MicroVision Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About MicroVision Inc.

Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M
Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream
Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements
Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now
Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens
Bioxytran Develops a Groundbreaking Treatment to Combat Bird Flu in Egg Laying Chickens Potentially Saving Billions
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.